세계의 생물제제 CDMO(개발제조수탁기관) 시장

Highlights:

The global market for biologics CDMOs is expected to increase from $15.1 billion in 2023 to $27.0 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.3% during the forecast period of 2023-2028.

The North American market for biologics CDMOs is expected to increase from $6.6 billion in 2023 to $12.4 billion by the end of 2028, with a CAGR of 13.2% during the forecast period of 2023-2028.

The Asia-Pacific market for biologics CDMOs is projected to increase from $3.1 billion in 2023 to $5.9 billion by the end of 2028, with a CAGR of 13.7% during the forecast period of 2023-2028.

Report Scope:

The scope of the report includes biologics CDMO services, industries, initiatives, patents, and companies. The markets for biologics CDMO are given for 2020, 2021, 2022, 2023 and 2028.

This report explains why biologics CDMO is important in pharmaceutical and biotechnology industry. It then discusses some of the significant research initiatives that are impacting biologics CDMO. The main market-driving forces are also discussed.

The report examines the markets by product type, cell line type and region. The report provides market data and forecasts for biologics CDMO by product type, including biologics and biosimilars. The specific regional markets covered are North America, Europe, Asia-Pacific and the Rest of the World (RoW).

In the report BCC Research summarizes the main industry acquisitions and strategic alliances from January 2020 through December 2022.

Report Includes:

• 40 data tables and 10 additional tables
• An up-to-date overview and industry analysis of the global markets for biologics contract development and manufacturing organizations (CDMO)
• Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
• Estimation of the actual market size and revenue forecast for biologics CDMO market in USD million values, and their corresponding market share analysis based on the product type, cell line type, and geographic region
• In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of macroeconomic variables on biologics CDMO marketplace
• Discussion of ESG developments in global CDMO services market, with emphasis on importance of ESG, consumer attitudes, risks and opportunity assessment, and ESG followed practices
• Identification of the pharma companies that are considered as leaders in their field, as well as technological means these companies are using to exploit their markets and dominate the market in their fields
• Market outlook and opportunity assessment of the industry structure for biologics CDMO services, and evaluation of ongoing clinical trials and R&D activities estimating current and future market demand
• Insight into the growth development strategies of the key market players operating within the global market; their key competitive landscape and company share analysis
• Analysis of the company competitive landscape based on recent developments, key financials, and operational integration
• Company profiles of major players within the industry, including Lonza Group, WuXi Biologics, Samsung Biologics, Boehringer Ingelheim, and Catalent Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Methodology
• Information Sources
• Geographic Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• Introduction
• Benefits of Biologics CDMOs
• Expertise
• Equipment and Manufacturing Facilities
• Scalability
• Benefits of Outsourcing
• Drawbacks to Outsourcing
• Contract Manufacturing
• Types of Contract Manufacturers
• Evolution of Contract Manufacturing Organizations
• Outsourcing
• Criteria for Evaluating a Contract Manufacturer
• Core Capabilities of CMOs
• Core Functional Areas Requiring Constant Attention
• Criteria for Selecting an Outsourcing Partner
• Top Sources of Dissatisfaction
• Challenges in Contract Manufacturing
• Services Offered by CMOs
• Contract Research
• Selecting a CRO
• Services Offered by CROs
• Checklist for Selecting a CRO
• Benefits of Using a CRO
• Client/CRO Relationship

Chapter 4 Market Dynamics

• Market Drivers
• Rising Prevalence of Cancer
• Increasing Demand for Biologics
• Rising Use of CDMOs
• Increasing Elderly Population
• Market Restraints
• Biologic Product Costs and Price Controls
• Capacity Constraints
• Manufacturing Costs
• Market Opportunities
• Co-development of Biosimilars

Chapter 5 Global Market for Biologics CDMOs by Product Type

• Introduction
• Biologics
• Biosimilars
• Biologics
• Biosimilars

Chapter 6 Global Market for Biologics CDMOs by Cell-Line Type

• Mammalian
• Microbial (Non-mammalian)
• Other Modalities

Chapter 7 Global Market for Biologics CDMOs by Region

• Market Overview and Discussion
• North America
• Europe
• Asia-Pacific
• RoW

Chapter 8 Sustainability in Biologics CDMOs: An ESG Perspective

• Introduction to ESG
• Sustainability in Biologics CDMO Industry: An ESG Perspective
• Key ESG Issues
• Attitudes toward ESG
• Industry ESG Performance Analysis
• Toyobo and ESG
• Concluding Remarks from BCC Research

Chapter 9 Emerging Technologies and Developments

• Overview
• Big Data, AI and ML
• Single-use Technology
• Process Analytical Technology (PAT)

Chapter 10 Regulatory Landscape

• Regulation of Biologics Services
• FDA Regulations
• European Regulations
• Impact of FDA Regulations
• The Declaration of Helsinki
• CDISC Standards

Chapter 11 M&A and Venture Funding Outlook

• M&A Analysis
• Recent News

Chapter 12 Competitive Intelligence

Chapter 13 Company Profiles

• ABBVIE PHARMACEUTICAL CONTRACT MANUFACTURING
• AGC BIOLOGICS
• BOEHRINGER INGELHEIM BIOXCELLENCE
• BINEX CO. LTD.
• BIOVIAN OY
• BORA PHARMACEUTICAL CDMO
• CATALENT INC
• CYTOVANCE BIOLOGICS
• EMERGENT BIOSERVICES
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• ICON PLC
• JRS PHARMA GMBH & CO. KG
• KEMWELL
• LONZA GROUP
• LOTTE BIOLOGICS
• PAREXEL INTERNATIONAL CORP.
• RENTSCHLER BIOPHARMA SE
• SAMSUNG BIOLOGICS
• SANDOZ INTERNATIONAL GMBH
• THERMO FISHER SCIENTIFIC INC.
• TOYOBO CO. LTD.
• WUXI XDC

Chapter 14 Appendix